Recent Price Movement and Volatility
On the day in question, Sunil Healthcare opened with a gap up of 6.82%, reaching an intraday high of Rs.68.9. However, the stock reversed course sharply, falling by 8.53% to close at Rs.59, its lowest level in the past year. This intraday volatility was notably high at 7.74%, indicating significant trading activity and uncertainty among market participants. The stock has been on a four-day losing streak, cumulatively declining by 13.01% during this period.
The stock’s performance today also lagged behind its Pharmaceuticals & Biotechnology sector peers, underperforming by 6.91%. This relative weakness highlights the challenges Sunil Healthcare faces within its industry context.
Technical Indicators Signal Bearish Momentum
From a technical perspective, Sunil Healthcare is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based weakness across multiple timeframes underscores the prevailing bearish sentiment. Additional technical indicators reinforce this outlook: the Moving Average Convergence Divergence (MACD) is bearish on both weekly and monthly charts, while Bollinger Bands and the Know Sure Thing (KST) indicator also signal downward momentum. The Dow Theory assessment is mildly bearish on weekly and monthly scales, further confirming the subdued technical environment.
Market Context and Broader Index Trends
The broader market environment has also been challenging. The Sensex opened lower at 74,415.79, down 0.2%, and was trading marginally down by 0.09% at 74,495.70 during the day. The index remains 4.12% above its own 52-week low of 71,425.01. Notably, the Sensex has been on a three-week consecutive decline, losing 8.35% over this period. It is trading below its 50-day moving average, which itself is positioned below the 200-day moving average, a classic bearish configuration. This overall market weakness has likely contributed to the pressure on Sunil Healthcare’s stock price.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Fundamental Performance and Financial Metrics
Sunil Healthcare’s fundamental profile continues to reflect challenges. The company’s long-term Return on Capital Employed (ROCE) averages a modest 5.21%, indicating limited efficiency in generating returns from its capital base. Net sales growth has been subdued, with an annualised increase of just 1.43% over the past five years. Additionally, the company’s ability to service debt remains constrained, as evidenced by a high Debt to EBITDA ratio of 5.63 times, signalling elevated leverage relative to earnings.
Despite these concerns, the company has reported positive earnings before tax for the last four consecutive quarters. The latest six-month Profit After Tax (PAT) stood at Rs.1.59 crore, with a half-year ROCE improving to 6.69%. The debt-equity ratio at half-year is relatively moderate at 0.88 times, suggesting some reduction in leverage compared to historical levels.
Valuation and Market Capitalisation
Sunil Healthcare is classified as a micro-cap stock, with a market capitalisation grade reflecting this status. The stock’s valuation metrics indicate an attractive enterprise value to capital employed ratio of approximately 1, suggesting that the market is pricing the company at a discount relative to its capital base. The Price/Earnings to Growth (PEG) ratio is notably low at 0.1, reflecting the disconnect between the company’s rising profits—up 275.5% over the past year—and its declining share price.
Over the last year, the stock has generated a negative return of 8.03%, underperforming the Sensex, which posted a modest gain of 0.98% during the same period. The broader BSE500 index delivered a 4.76% return, further highlighting Sunil Healthcare’s relative underperformance within the market.
Shareholding and Ownership Structure
The majority ownership of Sunil Healthcare remains with its promoters, who continue to hold a controlling stake in the company. This concentrated shareholding structure is typical for micro-cap companies in the Pharmaceuticals & Biotechnology sector.
Considering Sunil Healthcare Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Summary of Technical and Fundamental Ratings
Sunil Healthcare’s Mojo Score currently stands at 29.0, with a Mojo Grade of Strong Sell as of 2 Mar 2026, reflecting a downgrade from the previous Sell rating. This assessment is based on a combination of weak long-term fundamentals, subdued growth prospects, and bearish technical indicators. The stock’s consistent trading below key moving averages and negative momentum signals reinforce the cautious stance reflected in these ratings.
Conclusion
Sunil Healthcare Ltd’s stock reaching a 52-week low of Rs.59 is a culmination of sustained price weakness amid challenging market conditions and company-specific factors. The stock’s underperformance relative to sector peers and broader indices, combined with bearish technical signals and modest fundamental metrics, has contributed to this decline. While the company has shown some positive earnings trends in recent quarters, the overall market valuation and technical outlook remain subdued as of mid-March 2026.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
